Meronem (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, which blocks the cross‑linking of peptidoglycan strands. This disruption compromises cell wall integrity, leading to osmotic lysis and bacterial death. Its structure confers stability against most β‑lactamases, giving it activity against a wide range of Gram‑negative, Gram‑positive, and anaerobic organisms.

The dose of Meronem is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosing regimens are determined in a hospital environment and may be adjusted for special populations such as those with renal impairment.

Meronem falls under an unknown pregnancy category because limited human data are available. It should be used during pregnancy only when the potential benefit justifies any potential risk to the fetus. Caution is also advised for breastfeeding mothers, as the drug may be excreted in breast milk; a risk‑benefit assessment should be performed.

To order Meronem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and assist with any required import documentation.

Meronem offers a broad spectrum of activity and high stability against many β‑lactamases, similar to other carbapenems like imipenem and ertapenem. Compared with non‑carbapenem β‑lactams, it provides more reliable coverage of resistant Gram‑negative organisms, including Pseudomonas aeruginosa. Its dosing flexibility and lower propensity for drug‑induced seizures make it a preferred option in severe nosocomial infections.

Meronem powder for injection should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Once reconstituted, the solution should be used promptly according to the manufacturer’s instructions and discarded if not used within the recommended time frame.

Meronem is supplied as a sterile powder that must be reconstituted with a compatible diluent. The resulting solution is administered intravenously, typically over 15‑30 minutes, depending on the clinical situation and infusion guidelines. Administration is performed by qualified healthcare professionals in a controlled setting to ensure accurate dosing and monitor for adverse reactions.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can be life‑threatening. Prompt recognition of these events and immediate medical intervention are essential to mitigate harm.

Meronem should be avoided in individuals with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with severe renal impairment require dose adjustment; without appropriate modification, use may be contraindicated. Caution is also advised for patients with a history of seizures or uncontrolled epilepsy.